New psychoactive Substances - Ten-year overview of the situation in France
Tendances n° 127, OFDT, 8 p.
Ten years after the emergence of NPS, the available data reveal lower detection rates for new substances, and their use is still somewhat limited in France. This has not prevented these substances from gaining a foothold in certain user circles and occasionally being sought after by a wider audience.
Supply and dynamics of the phenomenon, substances used, user profiles, health consequences: this issue of Tendances covers the overall developments observed concerning these drugs. This is based on the knowledge developed by the OFDT via its TREND scheme, SINTES, the I-TREND project, and all information sources used by the French Monitoring Centre.
Two aspects specific to France may explain the limited impact of NPS. Firstly, there are no physical smartshops in France. The absence of such stores in France has slowed NPS consumption, particularly for brand-name substances. Furthermore, the editorial policy of French-speaking online discussion forums also plays a protective role: members are requested to only use the chemical names of the substances. This limits the visibility and appeal of substances for young users, along with the spread of inaccurate information.
Author : Magali Martinez, Thomas Néfau, Agnès Cadet-Taïrou
Download the PDF file (522 Ko)
Drugs in Europe
What do the latest data tell us about the European drug market? What are the new trends in drug use among European adults and school students? What are the harms associated with drug use and what is being done to counter them? These and other questions are explored in the 2018 EMCDDA European Drug Report.
Country drug reports 2018
Developed by the EMCDDA, in cooperation with the Reitox national focal points, these graphic-rich reports cover: drug use and public health problems; drug policy and responses and drug supply.
The European Union and the drug phenomenon
The European Union & the drug phenomenon : Frequently asked questions, joint publication between the EMCDDA and the European Commission, october 2010, 12 p.